Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221838 | 0.87 | — | — | |
| SCHEMBL20610035 | 0.83 | LMNA (0.56) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL9403620 | 0.83 | LMNA (0.56) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL632397 | 0.82 | LMNA (0.68) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL386229 | 0.82 | LMNA (0.68) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL238312 | 0.82 | LMNA (0.68) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL1193294 | 0.82 | LMNA (0.68) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL4808363 | 0.81 | LMNA (0.43) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL11238093 | 0.81 | LMNA (0.30) | LMNA | |
| SCHEMBL2701 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846739-B2 | TGR5 agonists | EXELIXIS PATENT COMPANY LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8785488-B2 | Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity | EXELIXIS PATENT COMPANY LLC (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2014100021-A1 | TGR5 AGONISTS: IMIDAZOLE AND TRIAZOLE COMPOUNDS CONTAINING A QUATERNARY NITROGEN | EXELIXIS, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100025-A1 | TGR5 AGONISTS HAVING AN IMIDAZOLE OR TRIAZOLE CORE WITH SUBTITUENT HAVING A QUATERNARY NITROGEN | EXELIXIS, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20130303505-A1 | TGR5 AGONISTS | EXELIXIS PATENT COMPANY LLC | 2013-11-14 | — | — | US | disclosed |
| CN-102372810-B | Method for preparing isomonoolefin-multiolefin copolymer | CHINA PETROLEUM & CHEMICAL | 2013-10-09 | — | — | CN | disclosed |
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| CN-102372822-B | Method for preparing isomonoolefin-multiolefin copolymer | CHINA PETROLEUM & CHEMICAL | 2013-06-12 | — | — | CN | disclosed |
| EP-0478545-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1992-04-08 | — | — | EP | disclosed |
| WO-1991004028-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-04-04 | — | — | WO | disclosed |
| EP-0413706-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-02-27 | — | — | EP | disclosed |
| EP-0218207-B1 | USE OF COMPLEX ESTERS IN SYNTHETIC LUBRICANTS, AND LUBRICANTS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1990-01-10 | — | — | EP | disclosed |
| WO-1989008647-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1989-09-21 | — | — | WO | disclosed |
| EP-0170076-B1 | HEAT TRANSFER FLUIDS | BASF Aktiengesellschaft (DE) | 1988-10-26 | — | — | EP | disclosed |
| WO-1988002366-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1988-04-07 | — | — | WO | disclosed |
| EP-0218207-A2 | Use of complex esters in synthetic lubricants, and lubricants containing them | BASF Aktiengesellschaft (DE) | 1987-04-15 | — | — | EP | disclosed |
| EP-0170076-A1 | Heat transfer fluids | BASF Aktiengesellschaft (DE) | 1986-02-05 | — | — | EP | disclosed |
| US-3944577-A | Novel pregnane-21-oic acid derivatives | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | LMNA 4206/4885MEN1 1681/4885CYP3A4 2623/4885 |
| US-20130303505-A1 | TGR5 AGONISTS | GCGR, NPY5R, TBXA2R | LMNA 2547/4885MEN1 4002/4885CYP3A4 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.